Suzhou Shengdia Biotechnology

Suzhou Shengdia Biotechnology is a clinical-stage biopharmaceutical company based in Suzhou, China, focused on the discovery and development of innovative small molecule therapeutics. The company primarily targets the Janus kinase (JAK) family and other signaling pathways to treat hematological malignancies and autoimmune disorders. Its lead candidate, SD-101, is a highly selective JAK2 inhibitor currently being evaluated in clinical trials for myelofibrosis and polycythemia vera. Additionally, Shengdia is developing SD-91, a selective TYK2 inhibitor for the treatment of psoriasis and other inflammatory conditions. The company leverages its expertise in medicinal chemistry to create differentiated drugs with improved safety and efficacy profiles.